1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

exclusivity gains shadow over Glenmark US Locoid generic launch

 
• By Anju Ghangurde

Glenmark Generics has launched its generic version of Astellas Pharma/Triax Pharmaceuticals' eczema treatment, Locoid Lipocream (0.1% hydrocortisone butyrate cream), on the US market, even as the contested presence of an authorized generic version is expected to take some sheen off the first-to-file opportunity.

Glenmark Generics has launched its generic version of Astellas Pharma/Triax Pharmaceuticals' eczema treatment, Locoid Lipocream (0.1% hydrocortisone butyrate cream), on the US market, even as the contested presence of an authorized generic version is expected to take some sheen off the first-to-file opportunity.

Glenmark, which is entitled to 180-days of exclusivity being the first to file an ANDA for the product, had earlier filed a lawsuit in the Court of Chancery of the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

More from Therapy Areas

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 
• By Andrew McConaghie

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.